Company Information & Drug Savings for CTI BioPharma Medications

CTI BioPharma is a biopharmaceutical company focused on developing treatments for myeloproliferative neoplasms (MPNs) and other blood cancers. The company created VONJO (pacritinib), a JAK2 inhibitor approved for intermediate or high-risk myelofibrosis with low platelet counts. CTI’s hematology-oncology research addresses serious blood disorders with limited treatment options.